Progression to Symptomatic Multiple Myeloma Predicted by Texture Analysis-Derived Parameters in Patients Without Focal Disease at F-FDG PET/CT.

Clin Lymphoma Myeloma Leuk

Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Published: August 2021

Unlabelled: This retrospective study is focused on the possible clinical implications of texture analysis-derived PET parameters in patients with smoldering multiple myeloma. Several texture features are significantly associated with progression to symptomatic multiple myeloma and with a shorter time to progression. The results of this study may lead to early identification of patients who could benefit from specific therapies.

Background: The aim of the study was to determine whether positron emission tomography parameters derived from texture analysis of axial and peripheral skeleton predict progression to symptomatic multiple myeloma (MM) in patients undergoing 18F-​fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) without evidence of focal sites of F-FDG uptake.

Patients And Methods: Patients with smoldering MM who underwent F-FDG PET/CT from May 2014 to June 2018 were retrospectively reviewed. Volumes of interest (VOIs) were placed on T5-T7 and L2-L4, iliac crests, and femoral diaphyses. Dedicated software (LIFEx) allowed us to obtain PET-derived first-, second-, and higher order texture features. Possible associations between PET parameters and progression to symptomatic MM were determined. Kaplan-Meier curves allowed to assess time to progression (TTP) based on the PET parameters.

Results: Forty-five patients were included: 26 patients (58%) did not meet the criteria for symptomatic MM, but 19 patients (42%) progressed to symptomatic MM. Several texture features extracted from VOIs placed on iliac crests and femoral diaphyses were significantly associated with progression to symptomatic MM and with a shorter TTP (P < .05); conversely, the above-mentioned parameters extracted from VOIs placed on T5-T7 and L2-L4 did not significantly differ among the patients with regard to their progression to symptomatic MM and length of TTP, except for the gray-level zone length matrix-short-zone low-gray-level emphasis and gray-level zone length matrix-low gray-level zone emphasis. Particularly, second- and higher order texture features showed a significant association with the above-mentioned outcomes.

Conclusion: Texture features derived from PET may be an expression of subtle disease distribution in the axial and peripheral bone marrow.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2021.03.014DOI Listing

Publication Analysis

Top Keywords

progression symptomatic
24
texture features
20
multiple myeloma
16
symptomatic multiple
12
f-fdg pet/ct
12
gray-level zone
12
patients
9
progression
8
texture
8
texture analysis-derived
8

Similar Publications

Background: The Knight Alzheimer Research Imaging (KARI) dataset, a compilation of data from projects conducted at Washington University in St. Louis, represents a comprehensive effort to advance our understanding of Alzheimer disease (AD) through multimodal data collection. The overarching goal is to characterize normal aging and disease progression to contribute insights into the biological changes preceding AD symptom onset.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.

Background: Autosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta-amyloid (Aβ) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of neurons, glial cells, and vasculature, at different disease stages appears ideal to developing and evaluating therapeutics.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

DZNE, Rostock, MV, Germany.

Background: In people with Parkinson's disease (PD), mutations in GBA and LRRK2 are associated with different clinical phenotypes which might be related to differential involvement of the cholinergic system. We aimed to investigate cholinergic basal forebrain (cBF) volume in asymptomatic and symptomatic mutation carriers in comparison to idiopathic PD and healthy controls and associations with cognitive decline.

Method: This study included 149 asymptomatic GBA and 169 asymptomatic LRRK2 mutation carriers, 112 LRRK2 carriers and 60 GBA carriers with PD, 492 idiopathic PD, and 180 healthy controls from the Parkinson's Progression Markers Initiative (PPMI).

View Article and Find Full Text PDF

Background: Primary Progressive Aphasia (PPA) is a clinical and symptomatic concept due to neurodegenerative diseases which language symptom was dominant from early clinical stage. PPA is categorized into 3 subtypes such as Progressive non-fluent aphasia (PNFA), Semantic dementia (SD), and logopenic progressive aphasia (LPA). In this study, we compared the differences of PPA subtypes depend on amyloid PET results.

View Article and Find Full Text PDF

Background: Semantic cognition refers to our ability to manipulate and generalize knowledge and plays a critical role in communication and daily activities. Therefore, impairments in semantic cognition can have a severe impact on quality of life (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!